Indivior Q3 net income more than triples to $137 million

• Indivior’s third-quarter 2026 GAAP net income more than tripled year-over-year to $137 million.
• Total net revenue rose 13% to $356 million, while SUBLOCADE net revenue climbed 22% to $267 million, both year-over-year.
• GAAP operating expenses fell 33% year-over-year to $125 million.
• The merger with Supernus is expected to close November 2, 2026; standalone full-year guidance will no longer apply upon completion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-436953), on October 29, 2026, and is solely responsible for the information contained therein.